Chorea News and Research

RSS
Tel Aviv University research links obsessive-compulsive disorder to common childhood illness

Tel Aviv University research links obsessive-compulsive disorder to common childhood illness

Prevalence of HD substantially underestimated in the UK

Prevalence of HD substantially underestimated in the UK

Accumulation of mutated protein may explain damaging cellular behavior in Huntington's disease

Accumulation of mutated protein may explain damaging cellular behavior in Huntington's disease

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

NeuroSearch's MermaiHD study supports potential Huntington's disease modifying properties of Huntexil

Presentation of results from open-label extension study of Xenazine

Presentation of results from open-label extension study of Xenazine

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

Cedars-Sinai Regenerative Medicine Institute supplies stem cells to aid Huntington's disease research

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

NIH awards Gladstone Institute consortium $3.7M for Huntington's disease research

HDSA honors outstanding contributors against Huntington's Disease

HDSA honors outstanding contributors against Huntington's Disease

Neurologix to showcase novel gene transfer approach to Parkinson’s disease

Neurologix to showcase novel gene transfer approach to Parkinson’s disease

New insights into identifying children at risk for autoimmune brain disorders

New insights into identifying children at risk for autoimmune brain disorders

Biovail acquires worldwide rights to Tetrabenazine

Biovail acquires worldwide rights to Tetrabenazine

First drug for Huntington's disease approved for use in the U.S.

First drug for Huntington's disease approved for use in the U.S.

FDA approves tetrabenazine for Huntington's disease

FDA approves tetrabenazine for Huntington's disease

Schizophrenia improved by mental and physical exercise

Schizophrenia improved by mental and physical exercise

Tetrabenazine protects brain cells in Huntington's disease model

Tetrabenazine protects brain cells in Huntington's disease model

Synaptic dysfunction in Huntington's disease

Synaptic dysfunction in Huntington's disease

Bioluminescence part of new imaging technique

Bioluminescence part of new imaging technique

New treatment possibilities for Huntington's disease

New treatment possibilities for Huntington's disease